Advertisement


Samuel Chao, MD, on Improving the Consistency of Radiation Oncology Processes

2015 ASTRO Annual Meeting

Advertisement

Samuel Chao, MD, of Cleveland Clinic, discusses the QMAP program and data-driven management, which offer ways to improve consistency and drive quality in radiation oncology departments (Abstract 39).



Related Videos

Palliative Care
Pain Management
Symptom Management

Alysa M. Fairchild, MD, on Preventing Radiation-Induced Pain Flare

Alysa M. Fairchild, MD, of the Cross Cancer Institute and the University of Alberta, discusses her study on the use of dexamethasone to reduce pain flare in patients receiving palliative radiotherapy for bone metastases (Abstract LBA6663).

Breast Cancer

Robert Kuske, MD, on PROMIS Registry Results

Robert Kuske, MD, of Arizona Breast Cancer Specialists, discusses the evaluation of more than 1,300 patients with accelerated partial-breast irradiation via multicatheter interstitial brachytherapy, focusing on toxicity and cosmetic outcomes (Abstract 133).

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Results of NRG Oncology/RTOG 9601

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses how adding 24 months of daily antiandrogen therapy during and after radiotherapy was shown to significantly improve long-term overall survival following prostate cancer recurrence after a radical prostatectomy (Abstract LBA5).

Lung Cancer

Roy Decker, MD, PhD, on Chemoradiation in Elderly Patients With Limited-Stage SCLC

Roy Decker, MD, PhD, of Yale University School of Medicine, discusses a National Cancer Database analysis that showed elderly patients with limited-stage small cell lung cancer can benefit from adding concurrent radiation to chemotherapy (Abstract 1010).

Prostate Cancer

James B. Yu, MD, on RTOG 0415: Fractionation Schedules in Patients With Low-Risk Prostate Cancer

James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).

Advertisement

Advertisement




Advertisement